Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Non-Current Liabilities (2019 - 2025)

Harmony Biosciences Holdings' Other Non-Current Liabilities history spans 7 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 188.55% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 188.55%, while the annual FY2025 figure was $5.6 million, 188.55% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $5.6 million at Harmony Biosciences Holdings, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.6 million in Q4 2025 and bottomed at $831000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $1.9 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Other Non-Current Liabilities soared 270.4% in 2022 before it crashed 49.52% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $3.2 million in 2021, then fell by 21.37% to $2.5 million in 2022, then decreased by 15.57% to $2.1 million in 2023, then dropped by 7.68% to $1.9 million in 2024, then soared by 188.55% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Other Non-Current Liabilities are $5.6 million (Q4 2025), $1.2 million (Q3 2025), and $1.4 million (Q2 2025).